Whalesbook
Covidh Technologies is set to acquire iSERA Biological Limited for ₹78 crore in a share swap deal, a move that will redefine the company's business. Enhanced limits for investments, loans, and guarantees up to ₹1,000 crore underscore significant growth ambitions.
Key Approvals Announced
The Board of Directors at Covidh Technologies Ltd has approved a major strategic shift. This includes a substantial increase in authorized share capital from ₹11 crore to ₹25 crore, creating an additional 1.40 crore equity shares.
The core of the plan is the acquisition of iSERA Biological Limited for ₹78 crore via a 1:1 share swap, which will make iSERA Biological a wholly-owned subsidiary. iSERA Biological is active in the pharmaceutical and life sciences sector and reported ₹18.36 crore in turnover for FY25.
Additionally, the board approved raising the limits for investments, loans, and guarantees under Section 186 of the Companies Act to ₹1,000 crore. This provides considerable financial flexibility.
The company also plans to change its name to iSERA Lifesciences Limited, reflecting its new business focus.
Strategic Pivot Explained
This acquisition represents a key step for Covidh Technologies, moving it from its established IT/ITES business into the growing pharmaceutical and life sciences industry. The goal is to build value and broaden its operations.
The increased authorized capital and higher financial limits offer substantial financial capacity for future growth, new investments, and managing debt.
Company History and Deal Background
Covidh Technologies Limited, founded in 1993 and previously known as Lordven Technologies Limited and Aptus Industries Limited, has historically operated in the IT/ITES sector. Filings show plans for a name change to 'iSERA Lifesciences Limited' effective April 10, 2026, pending member approval. The company is also emerging from the Corporate Insolvency Resolution Process (CIRP).
A Letter of Intent (LOI) dated February 23, 2026, for this acquisition was signed with iSERA Biological Private Limited. iSERA Biological, established in 2016, focuses on biotechnology, fermentation, and protein engineering within the pharmaceutical and life sciences sector.
Business Transformation Details
- New Focus: Covidh Technologies will become iSERA Lifesciences, dedicated to the pharmaceutical and life sciences industry.
- Subsidiary Status: iSERA Biological will operate as a wholly-owned subsidiary, integrating operations under the parent company.
- Financial Flexibility: Increased capital and higher financial limits will support growth and strategic projects.
- Market Standing: The acquisition aims to strengthen the company's position in the life sciences market.
Potential Risks and Challenges
- Regulatory Hurdles: The acquisition and capital increase require member approval through postal ballot/remote e-voting, alongside other regulatory clearances.
- Operational Integration: Successfully merging iSERA Biological's operations and achieving expected synergies is critical.
- Share Swap Fairness: Investors will evaluate the 1:1 share swap ratio and the valuation of iSERA Biological.
- Historical Governance: Past regulatory actions, including SEBI fines for stock manipulation and disclosure issues, remain a concern.
Competitive Landscape
Covidh's move into the pharmaceutical and life sciences sector means competing with established companies such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, and Biocon Limited. These firms have large market capitalizations and broad product ranges, highlighting the competitive environment iSERA Lifesciences will face.
iSERA Biological Performance
- iSERA Biological Limited reported a standalone turnover of ₹18.36 crore for the fiscal year ending March 31, 2025 (FY25).
Investor Watchlist
- Results of member approval via postal ballot or remote e-voting.
- In-principle approval from BSE Limited and other necessary regulators.
- Management's plan for integrating iSERA Biological and using the additional capital.
- Post-acquisition performance and initial operational synergy results.